Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study.

Ajay Kumar Ajmani,Aparna Agrawal, B L N Prasad,Indraneel Basu,Jayashree Shembalkar, Neeraj Manikanth, K A V Subrahmanyam, M Srinivasa,Manoj Chawla,Manoj Kumar Srivastava,Felix Jebasingh, A Basavprabhu, R P Agrawal,Rakesh K Pulichikkat,Ramdhan Meena, Shailaja Bhatia,Sandeep Kumar Gupta, Amol Dange,Ambrish Srivastava,Abhijit Trailokya, Vinayaka Shahavi, Sachin Shende

Diabetes Research and Clinical Practice（2019）

Cited 13|Views5

No score

Abstract

Evogliptin was non-inferior to sitagliptin in HbA reduction. It effectively improved glycemic control and was well tolerated in type 2 diabetes patients inadequately controlled by metformin alone.

Translated text

Key words

Evogliptin,Dipeptidyl peptidase-4 inhibitor,Type 2 diabetes mellitus,Sitagliptin

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined